



October 28, 2026

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Wednesday, October 28, 2026

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject; we, M/s Zota Health Care Limited (the “Company”), would like to inform you that the Board of Directors of the Company in its Meeting held on Wednesday, October 28, 2026 at 02:00 P.M. at Zota House, Bhagwan Aiyappa Complex, Next to Batliboi, Udhna-Navsari State Highway, Surat – 394210, Gujarat, have *inter alia*, discussed and approved the following business:

1. Considered and approved Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended on September 30, 2026 along with the Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith **(Annexure-1)**.

Unaudited Standalone and Consolidated Financial Results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at www.nseindia.com and on Company’s website at www.zotahealthcare.com.

The Board meeting concluded at 4:15 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,
For **Zota Health Care Limited**

Ashvin
Bhagavanb
hai Variya

Digitally signed by
Ashvin Bhagavanbhai
Variya
Date: 2026.10.28
16:52:16 +05'30'

Ashvin Variya
(Group Company Secretary & Compliance Officer)

Place: Surat
Encl.: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com
CIN: L24231GJ2000PLC038352

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zota Health Care Limited** (the "Company") **for the quarter and half year ended September 30, 2026** ("the Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Management's Responsibility

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 28/10/2026

Place: Surat

For Pradeep K. Singhi & Associates

Chartered Accountants

FRN : 0126027W

PRADEEPKUM
AR ANANDRAJ
SINGHI

Digitally signed by
PRADEEPKUMAR
ANANDRAJ SINGHI
Date: 2026.10.28 17:18:01
+05'30'

**Pradeep Kumar Singhi
(Partner)**

M. No. 200/024612

UDIN: 26024612IMDZZB7149

A/401, President Plaza, Near R.T.O. Office, Ring Road, Surat -395001

PH. No. 2474714 / 2474954 E-mail: info.surat@pradeepsinghi.com



ZOTA HEALTH CARE LIMITED

Unaudited Standalone Financial Results for the quarter ended 30th September, 2026

healthcare Ltd.

(Amount ₹ in Lakhs, except per share data)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30-09-2026 (Unaudited)	30-06-2026 (Unaudited)	30-09-2025 (Unaudited)	30-09-2026 (Unaudited)	30-09-2025 (Unaudited)	31-03-2026 (Audited)
I. Revenue from Operations	12606.54	12702.91	9942.42	25309.45	17743.12	40700.72
II. Other Income	389.50	394.26	326.71	783.76	550.10	1340.18
III. Total Income	12996.04	13097.17	10269.13	26093.21	18293.22	42040.91
IV. Expenses:						
Cost of Materials Consumed	154.99	236.97	288.85	391.97	779.38	1746.43
Purchases of Stock-in-Trade	8996.71	7704.85	4810.83	16701.56	8253.04	23674.65
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(1210.24)	(830.13)	336.39	(2040.37)	873.29	(2550.99)
Employee Benefit Expenses	1634.33	1238.95	1025.36	2873.28	2022.94	4889.32
Finance Costs	55.76	29.86	8.67	85.62	12.35	25.26
Depreciation / Amortisation and Depletion Expense	143.97	126.88	91.04	270.86	170.72	395.43
Other Expenses	3081.43	4329.54	2400.92	7410.97	4019.89	9785.45
Total Expenses	12856.96	12836.92	8962.07	25693.88	16131.61	37965.54
V. Profit before Exceptional items and tax from continuing operations (III-IV)	139.07	260.25	1307.05	399.32	2161.61	4075.36
VI. Exceptional Items						(98.96)
VII. Profit/(loss) before tax	139.07	260.25	1307.05	399.32	2161.61	3976.40
VIII. Tax Expense:						
(1) Current tax	28.03	75.99	332.17	104.01	555.85	1095.36
(1.1) I.T. & DD Tax Provision Created Short/ excess	-	-	-	-	-	(10.95)
(2) Deferred Tax	1.19	5.46	15.97	6.65	(24.47)	(101.34)
IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	112.24	189.72	990.85	301.96	1581.29	2790.66
X. Profit/(loss) before tax from discontinued operations						
XI. Tax Expense of discontinued Operations						
XII. Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)						
XIII. Profit/ (Loss) for the period	112.24	189.72	990.85	301.96	1581.29	2790.66
XIV. Other Comprehensive Income						
A (i) Items that will not be reclassified to Statement of profit and loss	12.66	(34.60)	-	(21.94)	(16.09)	50.81
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(3.19)	8.71	-	5.52	4.05	(12.79)
B (i) Items that will be reclassified to Statement of profit and loss	-	-	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-	-	-
(iii) Fair value changes on investments, net	-	-	-	-	-	-
Other comprehensive income for the period, net of tax	9.47	(25.90)	-	(16.42)	(12.04)	38.02
Total comprehensive income for the period (XIII + XIV)	121.71	163.82	990.85	285.54	1569.24	2828.68
Paid-up Equity Share Capital	3463.26	3463.26	3064.38	3463.26	3064.38	3463.26
Other Equity						85356.94
Earnings per equity share of face value of ₹ 10 each						
(1) Basic (in ₹)	0.32	0.55	3.27	0.87	5.30	8.48
(2) Diluted (in ₹)	0.32	0.55	3.12	0.87	5.05	8.48


* denotes figures less than a lakh

For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


(Managing Director)
Moxesh K. Zota
(Din : 07625219)


Company Secretary
Ashvin Variya
Date : 28-10-2026
Place : Surat


Chief Financial Officer
Vraj Mandviwala


Group CEO
Sujit Paul



For Pradeep K. Singhi & Associates

Chartered Accountants
Firm No. 0126027W

PRADEEP KUMAR
 ANANDRAJ SINGHI

Pradeep Kumar Singhi
(Partner)

M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
 Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
 Email: info@zotahealthcare.com
 Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
 Nr. Sachin Railway Station, Sachin,
 Surat - 394 230 (Guj.) India
 Ph: +91 261 2397122

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

**The Board of Directors of
Zota Health Care Limited**

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the **quarter and half year ended September 30, 2026** ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Regulation").

Management's Responsibility

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- i. Zota Health Care Limited (Parent)
- ii. Zota Healthcare Lanka (Pvt) Ltd (Wholly Owned Subsidiary)
- iii. Davaindia Health Mart Limited (Wholly Owned Subsidiary)
- iv. Zota Nex Tech Limited (Wholly Owned Subsidiary)

A/401, President Plaza, Near R.T.O. Office, Ring Road, Surat -395001

PH. No. 2474714 / 2474954 E-mail: info.surat@pradeepsinghi.com

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

- v. Everyday Herbal Beauty Care Limited (Subsidiary)
- vi. Everyday Herbal Beauty And Wellness Care Private Limited (Subsidiary)
- vii. Curexis Ventures Private Limited (Wholly Owned Subsidiary)
- viii. Globotask It Consultancy Services Private Limited (Subsidiary)
- ix. KMHP Ventures Limited(Wholly Owned Subsidiary)

Conclusion

Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

We did not review the interim financial statements of the subsidiaries included in the consolidated unaudited financial results that reflect total assets of Rs. 68155.11 Lakhs as at September 30, 2026, total revenues of Rs. 13914.83 Lakhs and Rs.25463.26 Lakhs, total net loss of Rs. 2875.70 Lakhs and Rs.6780.22 Lakhs and total comprehensive loss of Rs. 2794.04 Lakhs and Rs.6769.82 Lakhs, respectively for the quarter and half year ended September 30, 2026, and net cash flows of Rs. -1696.33 Lakhs for the half year ended September 30, 2026 as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For Pradeep K. Singhi & Associates
Chartered Accountants
FRN : 0126027W

Date: 28/10/2026

Place: Surat

PRADEEPKUMAR
ANANDRAJ SINGHI
Digitally signed by
PRADEEPKUMAR ANANDRAJ
SINGHI
Date: 2026.10.28 17:18:25
+05'30'

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

UDIN: 26024612VFJ10M7609

A/401, President Plaza, Near R.T.O. Office, Ring Road, Surat -395001

PH. No. 2474714 / 2474954 E-mail: info.surat@pradeepsinghi.com



ZOTA HEALTH CARE LIMITED

Unaudited Consolidated Financial Results for the quarter ended 30th September, 2026

(Amount ₹ in Lakhs, except per share data)

Zota Healthcare Ltd.		Quarter Ended			Half Year ended		Year Ended
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from Operations	19933.14	17360.23	12894.82	37293.37	23253.08	53865.75
II.	Other Income	485.69	204.34	163.65	690.03	251.26	743.75
III.	Total Income	20418.83	17564.57	13058.47	37983.39	23504.33	54609.50
IV.	Expenses:						
	Cost of Materials Consumed	154.99	236.97	288.85	391.97	779.38	1746.43
	Purchases of Stock-in-Trade	10071.23	8395.81	5847.62	18467.04	10033.22	28534.72
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(2287.13)	(2028.55)	(891.91)	(4315.68)	(1054.77)	(8884.30)
	Employee Benefit Expenses	7016.80	6112.50	3819.72	13129.30	7137.03	17832.98
	Finance Costs	635.66	635.24	382.82	1270.89	706.72	1736.11
	Depreciation / Amortisation and Depletion Expense	2866.46	2774.84	1850.79	5641.30	3318.63	8245.31
	Other Expenses	4671.22	5803.24	3198.48	10474.45	5330.50	12781.94
	Total Expenses	23129.24	21930.04	14496.38	45059.27	26250.72	61993.19
V.	Profit before Exceptional items and tax from continuing operations (III-IV)	(2710.41)	(4365.47)	(1437.91)	(7075.88)	(2746.39)	(7383.69)
VI.	Exceptional Items	-	-	-	-	-	(599.98)
VII.	Profit/(loss) before tax	(2710.41)	(4365.47)	(1437.91)	(7075.88)	(2746.39)	(7983.67)
VIII.	Tax Expense:						
	(1) Current tax	28.03	75.99	317.80	104.01	562.05	1095.36
	(1.1) I.T. & DD Tax Provision Created Short/ excess	-	-	-	-	-	(10.95)
	(2) Deferred Tax	142.42	46.99	136.33	189.41	311.28	1660.34
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	(2596.02)	(4394.47)	(1619.38)	(6990.49)	(2997.17)	(7407.74)
X.	Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XI.	Tax Expense of discontinued Operations	-	-	-	-	-	-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-	-	-
XIII.	Profit/ (Loss) for the period	(2596.02)	(4394.47)	(1619.38)	(6990.49)	(2997.17)	(7407.74)
XIV.	Other Comprehensive Income						
	A (i) Items that will not be reclassified to Statement of profit and loss	121.60	(129.66)	-	(8.07)	(14.04)	204.36
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(30.42)	32.48	-	2.07	3.53	(51.19)
	B (i) Items that will be reclassified to Statement of profit and loss	(0.05)	0.02	*	(0.03)	*	*
	(ii) Income Tax relating to items that will be reclassified to profit and loss	0.01	*	*	*	*	*
	Other comprehensive income for the period, net of tax	91.14	(97.16)	*	(6.02)	(10.51)	153.17
	Total comprehensive income for the period (XIII + XIV)	(2504.88)	(4491.63)	(1619.38)	(6996.51)	(3007.67)	(7254.56)
	Profit attributable to:						
	Owners of the parent	(2557.70)	(4355.51)	(1594.88)	(6913.22)	(3026.46)	(7393.61)
	Non-controlling interest	(38.32)	(38.96)	(24.49)	(77.27)	29.30	(14.13)
	Other comprehensive income attributable to:						
	Owners of the parent	90.86	(96.67)	0.36	(5.81)	(11.72)	152.42
	Non-controlling interest	0.28	(0.49)	(0.36)	(0.21)	1.22	-
	Total Comprehensive Income attributable to:						
	Owners of the parent	(2466.84)	(4452.19)	(1594.53)	(6919.03)	(3038.18)	(7241.19)
	Non-controlling interest	(38.04)	(39.45)	(24.85)	(77.48)	30.51	(14.13)
	Paid-up Equity Share Capital	3463.26	3463.26	3064.38	3463.26	3064.38	3463.26
	Other Equity	-	-	-	-	-	64481.81
	Earnings per equity share of face value of ₹ 10 each						
	(1) Basic (in ₹)	-7.39	-12.58	-5.26	(19.96)	(10.14)	(22.46)
	(2) Diluted (in ₹)	-7.39	-12.58	(5.02)	(19.96)	(9.66)	(22.46)

denotes figures less than a lakh

For and on behalf of the Board

(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)(Managing Director)
Moxesh K. Zota
(Din : 07625219)Company Secretary
Ashvin Variya
Date: 28-10-2026
Place: SuratChief Financial Officer
Virji MandviwalaGroup CEO
Sujit PaulFor Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027WPRADEEPKUMAR
ANANDRAJ SINGHIPradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com


CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Particulars	Standalone		Consolidated	
	As at	As at	As at	As at
	30th September, 2026 Unaudited	31st March, 2026 Audited	30th September, 2026 Unaudited	31st March, 2026 Audited
ASSETS				
(1) Non-Current Assets				
Property, plant and equipment	3033.12	3032.70	14053.61	14041.17
Right-of-use assets	-	-	22252.91	22435.93
Intangible Assets	492.89	409.24	600.84	433.99
Capital work-in-progress	0.00	0.00	530.49	171.06
Intangible assets under development	-	-	1323.87	1375.41
Financial Assets				
(i) Investments	59642.31	54787.97	16846.05	26388.47
(iii) Loans	80.28	13466.73	55.36	16.16
Deferred tax assets (Net)	(79.04)	(85.68)	2715.88	2526.41
Other Non-current assets	-	-	384.62	-
Total Non-Current assets	63169.56	71610.96	58763.62	67388.60
(2) Current Assets				
Inventories	10306.47	8317.67	23527.93	19263.83
Financial Assets				
(i) Trade Receivables	24030.62	17557.99	8454.41	7351.76
(ii) Cash and Cash Equivalents	0.92	0.70	862.04	776.77
(iii) Bank balance other than cash and cash equivalents	53.56	159.84	6892.99	8780.64
(iv) Loans	4589.10	1862.42	4307.77	3692.98
Other Current Assets	2667.34	2099.12	6579.77	5850.57
Total Current assets	41648.02	29997.73	50624.92	45716.55
Total Assets	104817.58	101608.69	109388.53	113105.14
EQUITY AND LIABILITIES				
(1) Equity				
(i) Equity Share capital	3463.26	3463.26	3463.26	3463.26
(ii) Other Equity	85772.35	85356.94	59096.52	65885.67
Non-controlling interest	-	-	190.15	267.63
Total Equity (Refer Note 1)	89235.61	88820.20	62749.93	69616.56
(2) Liabilities				
Non-Current Liabilities				
Financial Liabilities				
(i) Borrowings	-	-	653.49	636.94
(ii) Lease liabilities	-	-	17418.66	18357.94
Provisions	351.41	248.42	1225.69	766.42
Total non-current liabilities	351.41	248.42	19297.84	19761.30
Current liabilities				
Financial Liabilities				
(i) Borrowings	2550.04	2189.64	2550.04	2235.56
(ii) Lease liabilities	-	-	6491.96	5813.50
(ii) Trade payables	-	-	-	-
- Total outstanding dues of micro enterprises and small enterprises	3093.01	2146.29	3464.94	2479.38
- Total Outstanding dues of Creditors other than micro enterprises and small enterprises	6268.95	5498.32	4922.29	5500.89
Other Current liabilities	1599.49	978.88	2050.21	1200.62
Provisions	1719.07	1726.94	4396.39	4017.95
Total current liabilities	15230.56	12540.06	27340.76	23727.28
Total Liabilities	15581.97	12788.49	46638.60	43488.58
Total Equity and Liabilities	104817.58	101608.69	109388.53	113105.14

For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


(Managing Director)
Moxesh K. Zota
(Din : 07625319)

Company Secretary
Ashvin Variya

Chief Financial Officer
Viraj Mandviwala

Group CEO
Sujit Paul

Date: 28-10-2026
Place : Surat



For Pradeep K. Singhi & Associates

Chartered Accountants
Firm No. 0126027W

Pradeep Kumar
ANANDRAJ SINGHI

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352


Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

PARTICULARS	Consolidated		Standalone	
	Half year ended 30-09-2026 (Unaudited)	Half year ended 30-09-2025 (Unaudited)	Half year ended 30-09-2026 (Unaudited)	Half year ended 30-09-2025 (Unaudited)
A CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit Before Tax as per Statement of Profit and Loss	-7075.88	-2746.39	399.32	2161.61
Adjusted for:				
Exceptional items	-	-	-	-
Depreciation / Amortisation and Depletion Expense	5641.30	3318.63	270.86	170.72
Impact of loss & termination	10.03	-	-	-
Profit on sale of Property Plant & Equipment	-0.02	-	-0.02	-
Share based payments to employees	129.87	138.72	129.87	138.72
Interest Income	-452.62	-186.91	-762.81	-486.04
Finance Costs	1270.89	570.55	85.62	-
Operating Profit before Working Capital Changes	-476.42	1094.60	122.84	1985.01
Adjusted for:				
Trade Payables	1392.51	2009.17	1717.35	-382.19
Provisions-Current Liabilities	370.37	1282.08	-29.81	586.92
Provisions - Non-Current	459.27	220.31	102.99	62.96
Current Liabilities	849.59	-202.17	620.61	-566.25
Trade Receivables	-1102.65	-1764.03	-6472.64	-2147.49
Loans	-614.79	-2361.44	-2726.68	473.36
Inventories	-4264.11	-1214.98	-1988.80	713.07
Other Current and Non-current Assets	-1616.44	-415.76	-568.22	61.93
Changes in Working Capital	-4526.25	-2446.82	-9345.21	-1197.68
Cash Generated from Operations	-5002.67	-1352.22	-9222.36	787.34
Taxes Paid	-101.95	-558.53	-98.49	-551.80
Net Cash Flow from/(Used in) Operating Activities (A)	-5104.62	-1910.74	-9320.85	235.54
B CASH FLOW FROM INVESTING ACTIVITIES				
Purchase of Intangible Assets	-490.20	-4.26	-180.53	-4.26
Decrease in Long Term Loans & Advances	-39.20	-	13386.45	-3647.86
Interest Income	452.62	186.91	762.81	486.04
Interest - others	-406.00	-	-85.62	-
Proceeds from disposal of Property, Plant and Equipment and Intangible Assets	3.30	-	3.30	-
Purchase of Tangible Assets	-2233.40	-3672.15	-177.68	-543.10
Non-current Investments	9542.42	-3793.07	-4854.34	-8816.50
Net Cash Flow (Used in) Investing Activities (B)	6829.55	-7282.57	8854.40	-12525.68
C CASH FLOW FROM FINANCING ACTIVITIES				
Add: Adjustment for				
Proceeds from Issue of Equity Share Capital	-	200.88	-	200.88
Increase in Securities Premium Reserve	-	11937.60	-	11937.60
Decrease in short-term Borrowings	331.03	107.39	360.41	139.95
Money received against Share warrants	-	-	-	-
Purchase of non-controlling interest shares	-	-99.00	-	-
Principal payment of lease liability	-2993.45	-2113.15	-	-
Interest payment of lease liability	-864.90	-570.55	-	-
Net Cash Flow from / (Used in) Financing Activities (C)	-3527.31	9463.17	360.41	12278.43
Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	-1802.38	269.86	-106.05	-11.72
Opening Balance of Cash and Cash Equivalents	9557.41	361.91	160.53	134.99
Closing Balance of Cash and Cash Equivalents	7755.03	631.77	54.48	123.27


The accompanying notes are an integral part of the financial statements.
As per our report of even date

For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


(Managing Director)
Moxesh K. Zota
(Din : 07625219)


Ashvin Variya
(Company Secretary)


Viral Mandviwala
(Chief Financial Officer)


Sujit Paul
(Group Chief Executive Officer)

Date: 28-10-2026
Place: Surat

For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

PRADEEPKUMAR ANANDRAJ SINGHI
Digitally signed by PRADEEPKUMAR ANANDRAJ SINGHI
Date: 2026.10.28 17:19:01 +05'30'

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Notes:

1. The above financial results for the quarter and half year ended September 30, 2026 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on October 28, 2026.
2. The Financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.
3. The Statutory Auditors have carried out Limited Review with Unmodified review conclusion of the financial results for the quarter and half year ended September 30, 2026.
4. The Company has evaluated its Operating segment in accordance with Ind As 108 and has concluded that it is engaged in a single operating segment.
5. The Consolidated results include the result of following Companies:
 - A) Wholly Owned Subsidiaries:
 - i) Zota Healthcare Lanka (Pvt) Ltd
 - ii) Davaindia Health Mart Limited
 - iii) Zota Nex Tech Limited
 - iv) Curexis Ventures Private Limited
 - v) KMHP Ventures Limited
 - B) Subsidiaries:
 - i) Everyday Herbal Beauty Care Limited
 - ii) Everyday Herbal Beauty and Wellness Care Private Limited
 - iii) Globotask IT Consultancy Services Private Limited
6. In the Consolidated financial results, the Group has adopted Ind As 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 22252.91 lakhs and a corresponding Lease Liability of Rs. 23910.62 lakhs as at September 30, 2026. The impact of this on the consolidated profit for the quarter and half year ended September 30, 2026 is Rs. 193.41 lakhs and Rs. 372.53 lakhs respectively.
7. During the quarter, Company has made investment of Rs. 11952.23 lakhs by subscribing 2,35,512 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary of the Company, on a preferential basis for conversion of the outstanding Unsecured loan together with outstanding accumulated interest thereto, at an issue price of Rs. 5,075/- (including the premium of Rs. 5,065/-) per equity share.
8. Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

